ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1835

Systemic Lupus Erythematosus Does Not Increase Risk of Adverse Events in the First 6 Months after Total Knee Replacement

Arielle Fein1, Caroline Figgie1, Taylor Dodds2, Joshua Wright-Chisem3, Michael Parks4, Lisa Mandl5, Edwin Su6, Jane E. Salmon5,7, David J. Mayman4, Yuo-Yu Lee8, Mark P. Figgie2 and Susan M. Goodman7, 1Research, Hospital for Special Surgery, New York, NY, 2Orthopaedics, Hospital for Special Surgery, New York, NY, 3University of Illinois at Chicago College of Medicine, Chicago, IL, 4Orthopedics, Hospital for Special Surgery, New York, NY, 5Hospital for Special Surgery, New York, NY, 6Orthopedic Surgery, Hospital for Special Surgery, New York, NY, 7Rheumatology, Hospital for Special Surgery, New York, NY, 8Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: adverse events and osteoarthritis, SLE, Total Knee Arthroplasty (TKA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2015

Session Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: More Systemic Lupus Erythematosus (SLE)
patients are undergoing total knee arthroplasty (TKA) with equivalent benefits
to osteoarthritis (OA) patients. While post-surgical adverse events (AEs) are
increased after total hip arthroplasty, whether a similar increase occurs after
TKA is unknown. This study compares 6-month AEs in SLE and OA.

Methods: Patients enrolled in institutional arthroplasty and
lupus registries who underwent TKA between 2007 and 2014 were eligible for this
retrospective case-control study. SLE patients were identified by ICD-9 code
710.0 and confirmed by chart review. OA controls were matched 2:1 with SLE
cases on age, sex, year, and procedure. TKA for fractures were excluded.
6-month AEs were collected through chart review and a self-report
questionnaire. Baseline characteristics were compared and regression analysis was
performed to determine independent predictors of AE.

Results: 52 SLE TKA were matched to 104 OA. There were no
differences in mean age and sex (See Table 1). There was no difference in the
percentage of SLE vs. OA patients with complete 26-week follow-up (SLE 82.7%
vs. OA 79.6%; p-value=0.65). 38.4% of SLE patients had ≥1 Charlson-Deyo
comorbidity vs. 17.3% of OA (p-value<0.001; SLE not counted as a comorbidity).
Pre- and perioperative “stress-dose” steroid use were increased in SLE (28.8%
vs. 1.9%, p-value<0.001; 30.8% vs. 2.9%, p-value=0.01). Patients who received
stress-dose steroids did not experience more AEs (37.5% of SLE on steroids had
AEs vs. 38.9% SLE no steroids vs. 27.9% OA; p-value=0.40). SLE patients did not
experience more major (SLE 25.0% vs. OA 19.2%; p-value=0.41), minor (SLE 15.4%
vs. OA 10.6%; p-value=0.39), or total (SLE 38.5% vs. OA 27.9%; p-value=0.18)
AEs. In a multiple logistic regression analysis controlling for comorbidities, SLE
was not an independent risk factor for AEs (OR 1.61, 95% CI 0.74-3.50). Comorbidities
were also not significantly associated with AEs when controlling for diagnosis (OR
1.05, 95% CI 0.46-2.39).

Conclusion: Despite increased comorbidities and steroid use,
AEs are not increased in SLE patients after TKA and SLE is not an independent
risk factor for AEs. Stress-dose steroid use does not increase risk of AEs.
These important findings should guide recommendations for TKA in SLE patients.

Table 1: Patient Characteristics

 

SLE (n = 52)

OA (n = 104)

P value

Age (SD)

57.9 (14.7)

58.8 (11.6)

0.72

Female, n (%)

51 (98.1%)

102 (98.1%)

0.99

BMI (SD)

30.2 (8.3)

32.4 (8.2)

0.12

Unilateral, n (%)

22 (42.3%)

50 (48.1%)

0.87

Charlson-Deyo Comorbidity, n (%)*

 

 

0.001

         0 comorbidities

24 (46.2%)

86 (82.7%)

 

         1-2 comorbidities

19 (36.5%)

17 (16.3%)

 

         3+ comorbidities

1 (1.9%)

1 (1.0%)

 

Diabetes, n (%)

10 (19.2%)

13 (12.5%)

0.26

Anesthesia Type, n (%)

 

 

 

         Neuraxial

27 (51.9%)

60 (57.7%)

0.49

         General

2 (3.8%)

1 (1.0%)

0.26

         Regional

0

1 (1.0%)

0.99

         Adjunct Block

25 (48.1%)

40 (38.5%)

0.25

Length of Stay (SD)

5.4 (1.5)

5.0 (1.0)

0.06

Operative time (SD)

84.4 (23.6)

87.6 (23.8)

0.46

Coumadin as DVT Prophylaxis, n (%)

49 (94.2%)

88 (84.6%)

0.07

Pre-Operative Corticosteroid Use, n (%)

15 (28.8%)

2 (1.9%)

<.0001

Perioperative “Stress-Dose” Steroid Use, n (%)

16 (30.8%)

3 (2.9%)

0.01

Discharged to Inpatient Rehab, n (%)

26 (50.0%)

44 (42.3%)

0.09

Weeks of Follow-Up (SD)

23.2 (6.4)

22.8 (6.8)

0.72

Complete 6 Months (26 weeks) of Follow-Up, n (%)

43 (82.7%)

82 (79.6%)

0.65

*SLE excluded in comorbidity count; Comorbidity scores were missing in 15.4% of SLE patients.

Continuous variables were compared between groups using two-sample Student t-test. Categorical variables were compared between groups using Chi-square or Fisher exact test, as appropriate. Fisher exact test was used when 50% of the cells have expected count less than 5.

 

Table 2: Adverse Events

 

SLE (n = 52)

OA (n = 104)

P value

Major Events

 

 

 

Acute Renal Insufficiency

0 (0%)

0 (0%)

N/A

Arrhythmia

3 (5.8%)

4 (3.8%)

0.69

Deep Vein Thrombosis

0 (0%)

0 (0%)

N/A

Falls

1 (1.9%)

3 (2.9%)

0.99

Post-Operative Fracture

0 (0%)

1 (1.0%)

0.99

Dislocation

0 (0%)

0 (0%)

N/A

Manipulation

2 (3.8%)

9 (8.7%)

0.34

Additional Surgery (excluding manipulation)

7 (13.5%)

6 (5.8%)

0.13

Any Major Event

13 (25.0%)

20 (19.2%)

0.41

Minor Events

 

 

 

Superficial Surgical Site Infection

3 (5.8%)

1 (1.0%)

0.11

Excessive Surgical Site Drainage

2 (3.8%)

4 (3.8%)

0.56

Surgical Site Ecchymosis

1 (1.9%)

3 (2.9%)

0.99

Surgical Site Erythema

4 (7.7%)

4 (3.8%)

0.44

Spinal Headache

0 (0%)

1 (1.0%)

0.99

Delayed Wound Healing

1 (1.9%)

1 (1.0%)

0.99

Any Minor Event

8 (15.4%)

11 (10.6%)

0.39

Categorical variables were compared between groups using Chi-square or Fisher exact test, as appropriate. Fisher exact test was used when 50% of the cells have expected count less than 5.

 

Table 3: Adverse Events and Stress-Dose Steroid Use

 

 

SLE

Steroid

(n = 16)

SLE

No Steroid

(n = 36)

OA (n = 104)

P-Value

Any AE, n (%)

6 (37.5%)

14 (38.9%)

29 (27.9%)

0.40

Any Major AE, n (%)

4 (25.0%)

9 (25.0%)

20 (19.2%)

0.71

Number of AEs Experienced, n (%)

 

 

 

0.37

         0

10 (62.5%)

22 (61.1%)

75 (72.1%)

 

         1

5 (31.3%)

10 (27.8%)

21 (20.2%)

 

         2

0 (0%)

4 (11.1%)

5 (4.8%)

 

         3

0 (0%)

0 (0%)

2 (1.9%)

 

         4

1 (6.3%)

0 (0%)

1 (1.0%)

 

Categorical variables were compared between groups using Chi-square or Fisher exact test, as appropriate. Fisher exact test was used when 50% of the cells have expected count less than 5.

 

 


Disclosure: A. Fein, None; C. Figgie, None; T. Dodds, None; J. Wright-Chisem, None; M. Parks, Zimmer, Inc, 5,Orthopeadic Research and Education Foundation, 6,American Academy of Orthopaedic Surgery Orthopaedic Learning Center, 6,New York State Society of Orthopaedic Surgeons, 6; L. Mandl, Up To Date, 7,Annals of Internal Medicine, 9; E. Su, None; J. E. Salmon, None; D. J. Mayman, None; Y. Y. Lee, None; M. P. Figgie, None; S. M. Goodman, None.

To cite this abstract in AMA style:

Fein A, Figgie C, Dodds T, Wright-Chisem J, Parks M, Mandl L, Su E, Salmon JE, Mayman DJ, Lee YY, Figgie MP, Goodman SM. Systemic Lupus Erythematosus Does Not Increase Risk of Adverse Events in the First 6 Months after Total Knee Replacement [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/systemic-lupus-erythematosus-does-not-increase-risk-of-adverse-events-in-the-first-6-months-after-total-knee-replacement/. Accessed February 24, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-lupus-erythematosus-does-not-increase-risk-of-adverse-events-in-the-first-6-months-after-total-knee-replacement/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.